Secondary endpoints were changes in carotid plaque score ( in six regions ) , measures of glycaemia ( HbA1c , fasting glucose , and insulin concentrations , and Homeostasis Model Assessment of Insulin Resistance [ HOMA-IR ] ) , and concentrations of lipids , high sensitivity C-reactive protein , and tissue plasminogen activator .